COVID-19 Patients with New Atrial Fibrillation Face Higher Mortality Risk – A recent study published in Scientific Reports has revealed a concerning link between newly diagnosed atrial fibrillation (AF) and increased mortality in patients hospitalized with COVID-19. While pre-existing AF is known to be a risk factor for severe illness, this study suggests that the development of AF during COVID-19 itself can significantly worsen outcomes.
The study analyzed data from over 23,000 patients, providing robust results.
By focusing on regular users of the Veterans Health Administration, the study minimized misclassification of pre-existing AF.
What Is Atrial Fibrillation?
Atrial fibrillation, often abbreviated as Afib or AF, is a type of irregular heartbeat that occurs when the upper chambers of the heart, called the atria, quiver or twitch instead of beating normally. This quivering disrupts the regular pumping of blood from the heart to the rest of the body, which can lead to a variety of symptoms and complications.
Here’s a breakdown of what happens in Afib:
Normal heart rhythm: In a healthy heart, the electrical signals that control the heartbeat originate in a specialized area called the sinoatrial node (SA node). The SA node sends electrical impulses to the atria, causing them to contract and pump blood to the lower chambers of the heart, called the ventricles. The ventricles then contract and pump blood out to the rest of the body. This creates a regular, coordinated heartbeat.
Atrial fibrillation: In Afib, the electrical signals in the atria become chaotic and disorganized. This causes the atria to quiver or twitch instead of contracting normally. As a result, the ventricles may receive irregular and sometimes rapid electrical signals, causing the heart to beat irregularly and often faster than normal.
Key Findings:
- Higher Mortality Rate: Patients hospitalized for COVID-19 who develop atrial fibrillation (AF) for the first time (newly diagnosed) have a higher risk of dying in the hospital and within 30 days compared to those with a pre-existing AF diagnosis.
- Newer Patients Younger and Healthier: Interestingly, newly diagnosed AF patients were younger and had fewer cardiovascular and non-cardiovascular comorbidities compared to those with pre-existing AF.
- Potential for Misclassification: Previous studies may have underestimated the link between newly diagnosed AF and mortality due to inaccurate identification of pre-existing AF.
- Need for Further Research: More studies are needed to determine if newly diagnosed AF directly contributes to worse COVID-19 outcomes or simply reflects underlying health conditions. Additionally, strategies to prevent AF in COVID-19 patients are crucial.
Implications
This study highlights the importance of carefully monitoring COVID-19 patients for the development of AF, especially those with pre-existing risk factors.
Further research is needed to understand the mechanisms behind AF development in COVID-19 and to develop effective prevention and treatment strategies.
Study limitations
- Potential bias in AF diagnosis due to increased monitoring in COVID-19 patients.
- Survival analysis may have been affected by lack of precise AF onset timing.
- Didn’t consider echocardiographic features, limiting the analysis.
- Limited generalizability due to study population (mostly White Americans).
Study source
ALSO READ: Average Bottle Of Water Contains Cancer-causing Nanoplastic Pieces – Study Says
